News

The latest Research Assessment Exercise (RAE 2008) confirms Warwick Chemistry as one of the best Chemistry Departments in the UK. An impressive 75% of its research activity was rated as either world-leading (4*) or internationally excellent (3*) according to a panel of independent experts.  With all its academic staff submitted for the RAE, the Department can now confidently boast of excellence across all its research clusters.

A method for discovering entirely new career paths for existing clinical drugs is being exploited by start-up company Tangent Reprofiling Ltd., following a deal just signed between the company, PepTcell Limited, the University of Warwick and Warwick spin-out company a2sp Ltd.

The technique, developed at the University of Warwick, enables researchers to investigate potential new uses for drugs which are already approved for clinical use.

Tangent Reprofiling, set up as a subsidiary of the immunology company PepTcell, and based in High Wycombe, Buckinghamshire, has now acquired the intellectual property which will allow it to make use of the technique.

The idea of ‘reprofiling’ drugs is not unique to Tangent – perhaps the most famous example is the drug Viagra, which was originally developed to combat high blood pressure and angina. However this particular technique allows researchers to assess a wide landscape of current drugs in a cost and time efficient manner, using a combination of established chemical genomics techniques and proprietary chemistry.

Dr Suzanne Dilly, Tangent’s new CEO, explained, “Most drugs work by interacting with proteins in the body. By using the technology platform developed by a2sp Ltd, we can look for unexpected interactions between a drug and different proteins and then suggest potential new uses for that drug.

“One advantage of reprofiling drugs is that they have already gone through the rigorous tests required before a drug can be cleared for clinical use, a process which can take several years.”

A precious metal which has never before been used in a clinical setting is being developed as an anti-cancer agent by University of Warwick researchers. The metal, osmium, is closely related to platinum, which is widely used to treat cancers in the form of the drug cisplatin. Most famously, the cyclist Lance Armstrong was treated with cisplatin for testicular cancer.

Now the researchers, based in the Department of Chemistry, at the University of Warwick, are working closely with Warwick Ventures, the university’s technology transfer office, to seek partners to help develop the potential of osmium through more extensive biological tests. The team will be presenting their work on 9 December at the national university technology showcase event, Bioversity.

Professor Peter Sadler, of the Department of Chemistry, explained: "Although cisplatin has been proven to be a very successful treatment; it is not useful for all kinds of cancer. It is also quite a toxic therapy, which can produce side effects and, from a clinical point of view, cells can also become resistant to platinum."

Osmium, with its special chemical properties, offers a new potential solution to an unmet clinical need. It has shown huge promise in treating several different types of cancer cell, including ovarian and colon cancers which have been developed and tested in the laboratory. The metal also has another advantage in that it is a much cheaper alternative to platinum.

Peter Sadler was invited by the Massachusetts Institute of Technology (MIT, USA) to give the 2008-2009 Davison lecture in chemistry. His lecture was entitled:  Using metal coordination chemistry to design new medicines.

The Davison lecture was named after prof. Alan Davison, an Englishman who invented cardiolite and who spend most of his career at MIT, becoming emeritus in 2005.

“Cardiolite® is now the leading cardiac imaging agent in the world. It is the only heart imaging agent FDA-approved to non-invasively evaluate the heart’s pumping ability (function) and gauge the amount of blood flow to the heart muscle itself (perfusion). Cardiolite® topped $2 billion (USD) in cumulative sales in 2004, and is the single largest royalty earner in the entire MIT portfolio, providing even more revenue than the royalties associated with Professor John Sheehan’s patents describing synthetic penicillin.”

 

Chemistry researchers at The University of Warwick and the John Innes Centre, have found a novel signalling molecule that could be a key that will open up hundreds of new antibiotics unlocking them from the DNA of the Streptomyces family of bacteria.

With bacterial resistance growing researchers are keen to uncover as many new antibiotics as possible. Some of the Streptomyces bacteria are already used industrially to produce current antibiotics and researchers have developed approaches to find and exploit new pathways for antibiotic production in the genome of the Streptomyces family. For many years it was thought that the relatively unstable butyrolactone compounds represented by "A-factor" were the only real signal for stimulating such pathways of possible antibiotic production but the Warwick and John Innes teams have now found a much more stable group of compounds that may have the potential to produce at least one new antibiotic compound from up to 50% of the 1000 or so known Streptomyces family of bacteria.

Warwick Chemistry is rapidly becoming one of the best chemistry departments in the UK, as indicated by their current ranking of UK chemistry departments by the Times 2009 Good University guide 

Warwick Chemistry is heating up in becoming the top place in the UK to study chemistry with large investments in scientific infrastructure, for example £70 million under Science City in energy, translational medicine, and materials, thereby creating an impressive atmosphere for scientific research and education. 

This great environment continuously attracts many world-leading scientists to move from other top institutions, such as prof. Peter Sadler (FRS, transfer from Edinburgh, now Chair of Warwick Chemistry), Tim Jones (transfer from London Imperial), prof Peter O'Conner (Boston University, USA), Rachel O'Reilly (Cambridge University), and Giovanni Costantini (Max Planck Institute for Solid State Research, Germany).

Warwick Chemistry is currently recruiting about 120 undergraduates a year offering them world class education by enthusiastic scientists from its 5 research disciplines. Warwick Chemistry will continue to invest and expand its portfolio over the next few years with the ambition to be one of the top 3 in the UK.

 

Warwick Chemistry strengthens its portfolio in lectronic materials and in mass spectrometry with transfers of Ross Hatton from University of Surrey, and Peter O'Connor from Boston University (USA).

A new study by research chemists at the University of Warwick has challenged a century old rule of pharmacology that defined how quickly key chemicals can pass across cell walls. The new observations of the Warwick researchers suggest that the real transport rates could be up to a hundred times slower than predicted by the century old "Overton’s Rule". This could have major implications for the development and testing of many future drugs.

Overton’s rule says that the easier it is for a chemical to dissolve in a lipid (fat) the easier and faster it will be transported into a cell. The Rule was first outlined in the 1890s by Ernst Overton of the University of Zürich. He declared that substances that dissolve in lipids pass more easily into a cell than those that dissolve in water. He then set forth an equation that predicted how fast that diffusion would happen. One of the key parameters in that equation is K which defines the lipophilicity (oil-liking nature) of the chemical. The higher the value of K, the faster the predicted cell permeation rate. For over a century, medicinal chemists have used this relationship to shape their studies and clinical trials.

Commonly used industrial dyes hold the key to advancing the new science of 'spintronics', say researchers working on a new a £2.5 million study.

Spintronics holds out the possibility of a range of future applications, such as quantum computing, which aims to deliver secure, low-power computers capable of processing much larger quantities of data than is currently possible. Scientists believe that sensitive new biosensors able to analyse blood or urine samples rapidly and accurately could also be developed as a result of this work.

The new Basic Technology grant awarded by the Engineering and Physical Sciences Research Council will support research into the magnetic properties of metal atoms found in industrial dyes such as Metal Phthalocyanine (MPc), a blue dye used in clothing. The team from the London Centre for Nanotechnology - a joint venture between Imperial College London and University College London - and the University of Warwick believes that finding ways to control and exploit these molecules will allow spintronics to be applied in new ways.